Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Trading Halts

Viking Therapeutics (VKTX) Announces Proposed Common Share OfferingSeptember 19, 2018 4:23 PM Viking Therapeutic (VKTX) PT Raised to $28 at SunTrust Robinson HumphreySeptember 18, 2018 3:39 PM Viking Therapeutic (VKTX) PT Raised to $28 at Maxim Group, Matching 'Street High'September 18, 2018 12:31 PM Viking Therapeutic (VKTX) PT Raised to 'Street High' $28 at H.C. WainwrightSeptember 18, 2018 11:57 AM Viking Therapeutics (VKTX) Climbs 140% After Shares Resume TradingSeptember 18, 2018 7:37 AM Viking Therapeutics (VKTX) to Resume Trading at 7:35 am ETSeptember 18, 2018 7:17 AM Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-CholesterolSeptember 18, 2018 7:05 AM Viking Therapeutics (VKTX) Halted, News PendingSeptember 18, 2018 7:00 AM